Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study.

ABSTRACT:

Objective

To determine the time to efficacy onset of glatiramer acetate (GA) 40 mg/mL 3-times-weekly formulation (GA40).

Methods

This post hoc analysis of data from the 1-year, double-blind, placebo-controlled phase of the Glatiramer Acetate Low-Frequency Administration study (NCT01067521) of GA40 in patients with relapsing-remitting MS (RRMS) sought to determine the timing of efficacy onset using a novel data-censoring approach.

Results

Compared with placebo-treated patients, those receiving GA40 exhibited a >30% reduction in the accumulated annualized relapse rate (ARR) within 2 months of initiating treatment and generally sustained this treatment difference during the 1-year study. Similarly, the proportion of GA40-treated patients who remained relapse-free was dis

SUBMITTER: Davis MD 

PROVIDER: S-EPMC5299631 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature